Pegylated interferon and ribavirin treatment for hepatitis C virus infection

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 1, 2011, Pages 39-45

  Palumbo, Emilio ^a  

^a Hospital of Sondrio   (Italy)

Author keywords

hepatitis; hepatitis C virus; pegylated interferon; sustained response; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL ACTIVITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SINGLE DRUG DOSE; SUBSTANCE ABUSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 79960070664     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622310384308     Document Type: Review

References (18)

1. Caliceti P. (2004) Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 36: 334–339.
2. Douglas S. (2007) Hepatitis C seems milder in patients with hemophilia. Am J Gastroenterol 102: 1672–1676.
3. Freeman A.J. Dore G.J. Low M.G. Thorpe M. van Overhede J. Lloyd A.R. et al (2001) Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34: 809–816.
4. Fried M.W. Shiffman M.L. Reddy R. Smith C. Marinos G. Goncales F.L. Jr et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
5. Gerlach J.T. Diepolder H.M. Zachoval R. Gruener N.H. Jung M.C. Ulsenheimer A. et al (2003) Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80–88.
6. Hoefs J. Aulakh V.S. (2006) Treatment of chronic HCV infection in special populations. Int J Med Sci 3: 69–74.
7. Hoofnagle J.H. (2002) Course and outcome of hepatitis C. Hepatology 36(Suppl 1): S21–S29.
8. Huang R.H. Hu K.Q. (2006) A practical approach to managing patients with HCV infection. Int J Med Sci 3: 63–68.
9. Manns M.P. McHutchinson J.G. Gordon S.C. Rustgi V.K. Shiffman M. Reindollar R. et al (2001) Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965.
10. McHutchison J.G. Manns M.P. Brown R.S. Reddy K.R. Shiffman M.L. Wong J.B. (2007) Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 102: 880–889.
11. Patel K. McHutchison J.G. (2003) Current therapies for chronic hepatitis C. Postgrad Med 114: 48–52.
12. Pawlotsky J.M. (2005) Current and future concepts in hepatitis C therapy. Semin Liver Dis 25: 72–83.
13. Santantonio T. Fasano M. Sinisi E. Guastadisegni A. Casalino C. Mazzola M. et al (2005) Efficacy of a 24-week course of PEG-interferon alfa-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42: 329–333.
14. Scotto G. Fazio V. Fornabaio C. Tartaglia A. Di Tullio R. Saracino A. et al (2008) PEG-Interferon alfa 2° versus Peg-interferon alfa-2b in non-responders with HCV native chronic hepatitis: a pilot study. J Interferon Cytokine Res 28: 623–629.
15. Scotto G. Palumbo E. Fazio V. Cibelli D.C. Saracino A. Angarano G. (2005) PEG-interferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports. Infection 33: 30–32.
16. Seeff L.B. Hoofnagle J.H. (2002) National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 36(Suppl 1): S1–S2.
17. Strader D.B. Wright T. Thomas D.L. Seelf L.B. (2004) AASLD practice guideline: diagnosis, management and treatment of hepatitis C. Hepatology 39: 1147–1171.
18. Youngster S. Wang Y.S. Grace M. Bausch J. Bordens R. Wyss D.F. (2002) Structure, biology, and therapeutic implications of pegylated interferon alfa-2b. Curr Pharm Des 8: 2139–2157.